ADV1211: A Phase I Study of XL184 (Cabozantinib, IND# 116059) In Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors (ADVL1211)


Solid Tumor : Recurrent or refractory solid tumors, including CNS tumors


This is a Phase 1 study of a drug called XL184 (Cabozantinib). This is called a Phase 1 study because the goal is to find the highest dose of Cabozantinib that can be given safely. The study drug will be given as a tablet by mouth for 28 days at about the same time each day. This 28 day period is called a cycle. The cycles of the study drug may continue as long as there are no serious side effects and the tumor(s) does not get worse.

During the study, blood samples will be collected to study how the study drug affects different things in the body and the cancer.


Eligibility criteria, among others, include:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Wayne Furman, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only:

For all other inquiries about St. Jude Children's Research Hospital studies:

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.